Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Wake Forest University Health Scien

Neither a doctor nor a teaching hospital

Research payments

$1,146,506

250 payments

Through program year 2025, Wake Forest University Health Scien is reported as receiving $1,146,506 in research payments, across 250 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $619,986 77
2024 Research $116,057 23
2023 Research $130,781 22
2022 Research $97,394 31
2021 Research $116,940 60
2020 Research $47,800 32
2019 Research $17,548 5

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $367,999 36 payments
  2. GlaxoSmithKline, LLC. $249,634 108 payments
  3. Pfizer Inc. $237,727 34 payments
  4. AbbVie, Inc. $188,677 38 payments
  5. Astellas Pharma Global Development $36,488 16 payments
  6. Biosense Webster, Inc. $24,344 2 payments
  7. Genentech, Inc. $24,170 10 payments
  8. Sanofi US Services Inc. $15,500 1 payment
  9. Pharmacyclics LLC, An AbbVie Company $1,601 2 payments
  10. Medical Device Business Services, Inc. $366 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1 Study of Sgnegfrd2 in Advanced Solid Tumors $106,879 10 payments
  2. A Phase III, Randomized, Multicenter, Open-Label Study in Adolescent A $99,338 58 payments
  3. A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine After Allogeneic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia (AML) (VIALE-T) $99,214 8 payments
  4. A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms $91,379 7 payments
  5. A Phase 1 Openlabel Multicenter Study to Evaluate the Safety Tolerability Pharmacokinetics and Antitumor Activity of Sgnmesoc2 in Subjects With Advanced Solid Tumors $70,906 9 payments
  6. A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination with Daratumumab SC (Tal-D) and Teclistamab SC in Combination with Daratumumab SC (Tec-D) Following Induction with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants with Standard-risk Newly Diagnosed Multiple Myeloma $46,477 2 payments
  7. A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. $44,900 3 payments
  8. A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma $43,020 1 payment
  9. A Phase Iiib, Multi-Center, Non-Randomized, Parallel-Group, Open-Label $41,621 5 payments
  10. A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Receivedat Least 1 Prior Line of Therapy $33,782 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record